FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136379329> ?p ?o ?g. }

• W3136379329 endingPage "e002355" @default.
• W3136379329 startingPage "e002355" @default.
• W3136379329 abstract "The most common clinical outcome observed after treatment with immune checkpoint inhibitor antibodies is disease stabilization. Using vaccines to generate high levels of tumor antigen-specific T-helper 1 (Th1), we show that tumors not eradicated by vaccination demonstrate prolonged disease stabilization. We evaluated the mechanism by which type I T cells inhibit disease progression and potentially influence the subsequent clinical response to standard therapy in treatment refractory cancers.We employed a meta-analysis of studies with tumor growth from four different vaccines in two different mammary cancer models. The T-cell subtype and cytokine essential for vaccine-induced tumor inhibition was determined by in vivo neutralization studies and immunohistochemistry. The role of interferon gamma (IFN-γ) in receptor tyrosine kinase and downstream signaling was determined by immunoblotting. The role of suppressor of cytokine signaling 1 (SOCS1) on IFN-γ signaling was evaluated on SOCS1-silenced cells with immunoblotting and immunoprecipitation. The effect of vaccination on growth factor receptor signaling pathways, performed in both luminal (TgMMTVneu) and basal (C3(1)-Tag) mammary cancer models treated with paclitaxel or an anti-HER2-neu monoclonal antibody were assessed via immunoblotting.Immunization with an epitope-based vaccine targeting a representative tumor antigen resulted in elevated tumor trafficking Tbet+CD4 T cells, decreased tumor proliferation and increased apoptosis compared with control vaccinated mice. The resulting disease stabilization was dependent on IFN-γ-secreting CD4+ T cells. In the presence of excess IFN-γ, SOCS1 became upregulated in tumor cells, bound insulin receptor, insulin like growth factor receptor 1 and epidermal growth factor receptor resulting in profound oncogenic signaling inhibition. Silencing SOCS1 restored growth factor receptor signaling and proliferation and prevented cell death. Similar signaling perturbations were detected in vaccinated mice developing antigen-specific Th1 cells. Vaccination synergized with standard therapies and restored disease sensitivity to treatment with both a neu-specific antibody and paclitaxel in TgMMTVneu and to paclitaxel in C3(1)-Tag. Combination of vaccination and chemotherapy or biological therapy was more effective than monotherapy alone in either model and resulted in complete resolution of disease in some individuals.These data suggest the clinical activity of type I T cells extends beyond direct tumor killing and immune therapies designed to increase type I T cells and could be integrated into standard chemotherapy regimens to enhance therapeutic efficacy." @default.
• W3136379329 created "2021-03-29" @default.
• W3136379329 creator A5007473945 @default.
• W3136379329 creator A5021046796 @default.
• W3136379329 creator A5050287661 @default.
• W3136379329 creator A5060432567 @default.
• W3136379329 creator A5075270502 @default.
• W3136379329 date "2021-03-01" @default.
• W3136379329 modified "2023-10-10" @default.
• W3136379329 title "Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways" @default.
• W3136379329 cites W1959848155 @default.
• W3136379329 cites W1964832108 @default.
• W3136379329 cites W1976577472 @default.
• W3136379329 cites W1982488143 @default.
• W3136379329 cites W1985123547 @default.
• W3136379329 cites W1991296878 @default.
• W3136379329 cites W1998388200 @default.
• W3136379329 cites W2032969255 @default.
• W3136379329 cites W2049491375 @default.
• W3136379329 cites W2080641261 @default.
• W3136379329 cites W2081796577 @default.
• W3136379329 cites W2097540535 @default.
• W3136379329 cites W2106434365 @default.
• W3136379329 cites W2112818491 @default.
• W3136379329 cites W2114101532 @default.
• W3136379329 cites W2116201594 @default.
• W3136379329 cites W2126393987 @default.
• W3136379329 cites W2143450041 @default.
• W3136379329 cites W2147622445 @default.
• W3136379329 cites W2159753688 @default.
• W3136379329 cites W2160344066 @default.
• W3136379329 cites W2162638357 @default.
• W3136379329 cites W2164151058 @default.
• W3136379329 cites W2168499174 @default.
• W3136379329 cites W2345415641 @default.
• W3136379329 cites W2417570321 @default.
• W3136379329 cites W2471873673 @default.
• W3136379329 cites W2496085280 @default.
• W3136379329 cites W2564006575 @default.
• W3136379329 cites W2597637198 @default.
• W3136379329 cites W2613155082 @default.
• W3136379329 cites W2655262992 @default.
• W3136379329 cites W2738780043 @default.
• W3136379329 cites W2765962239 @default.
• W3136379329 cites W2774816960 @default.
• W3136379329 cites W2775759880 @default.
• W3136379329 cites W2796153225 @default.
• W3136379329 cites W2799849968 @default.
• W3136379329 cites W2800071778 @default.
• W3136379329 cites W2801285271 @default.
• W3136379329 cites W2985145778 @default.
• W3136379329 cites W3015953783 @default.
• W3136379329 cites W3047879827 @default.
• W3136379329 cites W788288083 @default.
• W3136379329 doi "https://doi.org/10.1136/jitc-2021-002355" @default.
• W3136379329 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7993179" @default.
• W3136379329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33762321" @default.
• W3136379329 hasPublicationYear "2021" @default.
• W3136379329 type Work @default.
• W3136379329 sameAs 3136379329 @default.
• W3136379329 citedByCount "5" @default.
• W3136379329 countsByYear W31363793292021 @default.
• W3136379329 countsByYear W31363793292022 @default.
• W3136379329 countsByYear W31363793292023 @default.
• W3136379329 crossrefType "journal-article" @default.
• W3136379329 hasAuthorship W3136379329A5007473945 @default.
• W3136379329 hasAuthorship W3136379329A5021046796 @default.
• W3136379329 hasAuthorship W3136379329A5050287661 @default.
• W3136379329 hasAuthorship W3136379329A5060432567 @default.
• W3136379329 hasAuthorship W3136379329A5075270502 @default.
• W3136379329 hasBestOaLocation W31363793291 @default.
• W3136379329 hasConcept C121608353 @default.
• W3136379329 hasConcept C126322002 @default.
• W3136379329 hasConcept C128240485 @default.
• W3136379329 hasConcept C14077384 @default.
• W3136379329 hasConcept C170493617 @default.
• W3136379329 hasConcept C179185449 @default.
• W3136379329 hasConcept C203014093 @default.
• W3136379329 hasConcept C2777701055 @default.
• W3136379329 hasConcept C2778690821 @default.
• W3136379329 hasConcept C42362537 @default.
• W3136379329 hasConcept C502942594 @default.
• W3136379329 hasConcept C62478195 @default.
• W3136379329 hasConcept C71924100 @default.
• W3136379329 hasConcept C86803240 @default.
• W3136379329 hasConcept C8891405 @default.
• W3136379329 hasConcept C95444343 @default.
• W3136379329 hasConceptScore W3136379329C121608353 @default.
• W3136379329 hasConceptScore W3136379329C126322002 @default.
• W3136379329 hasConceptScore W3136379329C128240485 @default.
• W3136379329 hasConceptScore W3136379329C14077384 @default.
• W3136379329 hasConceptScore W3136379329C170493617 @default.
• W3136379329 hasConceptScore W3136379329C179185449 @default.
• W3136379329 hasConceptScore W3136379329C203014093 @default.
• W3136379329 hasConceptScore W3136379329C2777701055 @default.
• W3136379329 hasConceptScore W3136379329C2778690821 @default.
• W3136379329 hasConceptScore W3136379329C42362537 @default.
• W3136379329 hasConceptScore W3136379329C502942594 @default.

• next